IN8bio, Inc.
2.0000-0.10 (-4.76%)
Oct 29, 4:00:00 PM EDT · NasdaqCM · INAB · USD
Key Stats
Market Cap
9.08MP/E (TTM)
-Basic EPS (TTM)
-9.16Dividend Yield
0%Recent Filings
8-K
8-K
IN8bio cuts losses, extends cash
IN8bio reported Q2 2025 net loss of $5.1 million, down from $8.6 million last year, thanks to slashed R&D spending on paused INB-400 trials and leaner staffing. Cash climbed to $13.2 million, stretching runway to June 2026. Yet a glioblastoma patient hit four-year progression-free survival on INB-200, doubling median PFS to 16.1 months versus standard care. Upcoming leukemia and GBM updates loom large.
10-Q
Q2 FY2025 results
IN8bio narrowed its Q2 net loss to $5.1M from $8.6M y/y, as research and development expenses dropped 52% to $2.5M amid pipeline prioritization and headcount reductions, while general and administrative costs fell 23% to $2.7M. Operating expenses for the half-year declined 37% y/y to $10.9M, yielding a $10.6M net loss versus $17.2M last year; diluted EPS improved to $(1.24) from $(5.51) y/y and $(3.65) for the half, reconciling to 4.1M weighted shares. Cash burn eased to $7.0M for the half from $14.0M y/y, with $13.2M cash on hand funding operations into June 2026, bolstered by $9.2M in financing from ATM sales and warrant exercises. No free cash flow disclosed in the 10-Q. Positive INB-200 data showed 16.1-month median PFS in glioblastoma patients, doubling standard-of-care benchmarks. Yet, funding constraints pose a key risk, with substantial doubt on going concern status.
8-K
Regains Nasdaq compliance
8-K
IN8bio completes reverse split
IN8bio executed a 1-for-30 reverse stock split effective June 5, 2025, slashing outstanding shares from 103,327,028 to about 3,444,234 to meet Nasdaq listing standards. This move, approved by shareholders on May 8, preserves ownership percentages while cashing out fractional shares. Trading resumes split-adjusted on June 6. Yet, it signals persistent compliance pressures.
ACET
Adicet Bio, Inc.
0.75-0.11
ETNB
89bio, Inc.
14.84+0.00
IBIO
iBio, Inc.
1.54+0.15
IMTX
Immatics N.V.
10.34-0.02
INBX
Inhibrx Biosciences, Inc.
77.05+8.56
INDP
Indaptus Therapeutics, Inc.
3.34-0.11
INMB
INmune Bio Inc.
1.82+0.00
INO
Inovio Pharmaceuticals, Inc.
2.43-0.15
IOBT
IO Biotech, Inc.
0.87-0.03
MBIO
Mustang Bio, Inc.
1.47-0.03